Screener
Zymeworks ZYME ZW220 — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Zymeworks in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The source filing: Zymeworks’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001937653-26-000047
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Revenue | ||||
| Research and development collaborations | $4,590 | $48,726 | $6,998 | $75,836 |
| Operating expenses: | ||||
| Research and development | 27,435 | 34,449 | 61,892 | 70,187 |
| General and administrative | 19,335 | 14,951 | 34,404 | 31,936 |
| Total operating expenses | 46,770 | 49,400 | 96,296 | 102,123 |
| Loss from operations | (42,180) | (674) | (89,298) | (26,287) |
| Other (expense) income: |
Item 1. Financial Statements
FAQ
- What is Zymeworks's ZW220 — R&D?
- Zymeworks (ZYME) reported ZW220 — R&D of -$152K in Q2 2026.
- What does ZW220 — R&D mean?
- This metric represents the total investment allocated to the research and development activities specifically associated with the ZW220 product candidate. It captures the resources dedicated to advancing this specific therapeutic asset through its clinical development lifecycle. Monitoring this spend helps investors assess the company's commitment to and progress of this particular pipeline program.
Ask your AI about Zymeworks's zw220 — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude